Tests for detection of ROS1 gene alterations in patients with non-small cell lung cancer - Protocol for a rapid review
Project
|Last update
The NIPH will evaluate genomic tests relevant for the identification of somatic ROS1 gene alterations in patients with locally advanced or metastatic non-small cell lung cancer.
Summary
The Institute of Public Health has been commissioned to evaluate genomic tests relevant for the identification of somatic ROS1 gene alterations in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The Norwegian Medicines Agency (NoMA) will evaluate the treatment effect and safety of the drug Entrectinib (Rozlytrek) in the same population.
Project leader
Gerd Monika Flodgren, Norwegian Institute of Public Health
Project participants
Vida Hamidi, Norwegian Institute of Public Health
Elisabet Vivianne Hafstad, Norwegian Institute of Public Health
Start
23.09.2020
End
15.02.2021
Status
Concluded
Project owner/ Project manager
Norwegian Institute of Public Health